Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Opioid Manufacturers Should Prepare For A Tobacco Moment

Executive Summary

US Senate Democrats are eager to bring in prescription opioid manufacturer executives for a hearing that would recreate the famous image of tobacco industry CEOs being sworn in by Congress. That moment probably won’t come this year – but may be inevitable before the opioid abuse crisis can be declared over.

You may also be interested in...



US Medicare And Opioids: Inspector General Sees Improvement

HHS is slowly changing its rhetoric on the use of prescription opioids – edging away from crisis to finding positive trends. A new OIG report on opioid use in Medicare Part D emphasizes sustained positive trends in naloxone rescue and medication assisted treatment alternatives to opioid use disorder.

Big Pharma CEOs Get Ready To Testify: Preparing For A No-Win Situation

Here is what to expect from – and some free advice for – seven industry executives as they prepare for a hearing on drug pricing in the Senate Finance Committee.

Pharma’s Blame-The-Middleman Strategy Pays Off – For Now

Success of drug industry’s campaign to highlight role of 'middlemen' in the supply chain was never more clear than during President Trump’s Rose Garden drug pricing event. But what happens now that the attention is turned squarely back on manufacturers?

Related Content

Topics

UsernamePublicRestriction

Register

PS123044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel